Zoom

Beijing Zoom Biopharmaceutical is a Chinese biotechnology company dedicated to the development and production of recombinant protein drugs, with a primary focus on hematological disorders. The company's flagship program is a recombinant human coagulation factor VIIa (rhFVIIa), which is designed to treat hemophilia patients with inhibitors and those with congenital factor VII deficiency. By leveraging its proprietary recombinant protein platform, Zoom Biopharmaceutical aims to provide high-quality, domestically produced alternatives to expensive imported bypass agents. The company operates integrated R&D and manufacturing facilities in Beijing to support its clinical pipeline and future commercialization efforts. Its work is significant in the context of the Chinese healthcare market's push for self-sufficiency in critical biologic therapies.